We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
PLUVICTO Novartis Pharmaceuticals Australia Pty Ltd
Product name
PLUVICTO
Accepted date
Jul-2025
Active ingredients
lutetium (177Lu) vipivotide tetraxetan
Proposed indication
Pluvicto (lutetium [177Lu] vipivotide tetraxetan) is proposed as a treatment for adults with advanced prostate cancer that has spread and no longer responds to hormone therapy. It is used in patients when the cancer shows a specific marker (called PSMA) and after patients have already been treated with hormone-blocking medicines and, in some cases, chemotherapy.
Application type
C (new indication)
Publication date
Jul-2025